Half-Year 2022 Financial and Clinical Trials Update

Crovalimab (RG6107; SKY59) A humanized monoclonal antibody against complement C5 Indication Sickle cell disease (SCD) acute treatment Sickle cell disease (SCD) chronic VOC prevention Phase/study # of patients Design Phase lb CROSSWALK-a N=30 ARM A: Crovalimab ARM B: Placebo Primary endpoint Safety FPI Q1 2022 Status CT Identifier SCD-Sickle Cell Disease; VOC-Vaso-occlusive crises NCT04912869 Phase lla CROSSWALK-C N=90 ARM A: Crovalimab ARM B: Placebo VOC rate, up to 48 weeks ☐ FPI Q1 2022 NCT05075824 142 Roche Immunology

View entire presentation